Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2015, No. 3


Celis MÁ, Alegría-Loyola MA, González-Aguilar A, Martínez-Tlahuel J, Green-Renner D, Reyes-Soto G, Arellano-Reynoso A, Flores-Castro JM, Moreno-Jiménez S, Poitevin-Chacón MA, Cacho-Díaz B, Olvera-Manzanilla E, Díaz-Victoria AR, Aguilar-Castañeda E, Granados-García M, Rodríguez-Orozco J, Herrera-Goepfert R, Álvarez-Avitia MÁ
Primer consenso mexicano sobre recomendaciones de la atención multidisciplinaria del paciente con glioblastoma multiforme (GBM). Grupo Interdisciplinar Mexicano de Investigación en Neurooncología (GIMINO)
Gac Med Mex 2015; 151 (3)

Idioma: Español
Referencias bibliográficas: 34
Paginas: 403-415
Archivo PDF: 269.70 Kb.


Texto completo




RESUMEN

El GBM es uno de los tumores más agresivos y con peor pronóstico del sistema nervioso central. Los tratamientos aplicados hasta el momento han logrado aumentar sensiblemente la supervivencia de estos pacientes, dependiendo de la edad, el estado cognitivo y la autonomía de los propios individuos. En función de estos parámetros se realiza tanto el tratamiento inicial como en la recurrencia, así como el seguimiento de la enfermedad mediante estudios de imagen. Una vez que el paciente entra en fase terminal y se suspenden los tratamientos curativos, se ha de garantizar el respeto a la voluntad anticipada y el desarrollo y aplicación de las terapias paliativas.


Palabras clave: Glioblastoma multiforme, Astrocitoma grado IV, Bevacizumab, Tumor cerebral maligno.


REFERENCIAS

  1. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892-9.

  2. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer. 2004;100(12):2622-6.

  3. Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol.;104(3):639-46.

  4. Scherling CS, Smith A. Opening up the window into «chemobrain»: a neuroimaging review. Sensors (Basel). 2013;13(3):3169-203.

  5. NCCN Guidelines Version 2.2013. Anaplastic Gliomas and Glioblastoma.

  6. Dandy WE. Physiological studies following extirpation of the right cerebral hemisphere in man. Bulletin of The Johns Hopkins Hospital. 1933;53.

  7. Hart MG, et al. Biopsy versus resection for high grade glioma. Cochrane Database of Systematic Reviews. 2011

  8. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753-64.

  9. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5): 392-401.

  10. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88.

  11. Forsyth PA, Petrov E, Mahallati H, et al. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol. 1997;15(5):2076-81.

  12. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66.

  13. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005;353(8):811-22.

  14. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527-35.

  15. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583-8.

  16. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874-80. Erratum in: J Clin Oncol. 2010;28(4):708.

  17. Kaloshi G, Petrela M. Carboplatin chemotherapy in patients with recurrent high-grade glioma. Clin Oncol (R Coll Radiol). 2011;23(7):495.

  18. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5(10):1725-31.

  19. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of highgrade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20(6):1635-42.

  20. Reddy K, Damek D, Gaspar LE, et al. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;84(3):655-60.

  21. Levivier M, Wikler D Jr, Massager N, et al. The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg. 2002;97(5 Suppl):542-50.

  22. Binello E, Green S, Germano IM. Radiosurgery for high-grade glioma. Surg Neurol Int. 2012;3(Suppl 2):S118-26.

  23. Nwokedi EC, DiBiase SJ, Jabbour S, Herman J, Amin P, Chin LS. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery. 2002;50(1):41-6.

  24. Nagai H. Results Following Stereotactic Radiosurgery for Patients with Glioblastoma multiforme. Radiosurgery. 2004;5:91-9.

  25. Cairncross JG, Pexman JH, Rathbone MP. Post-surgical contrast enhancement mimicking residual brain tumour. Can J Neurol Sci. 1985;12(1):75.

  26. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-72.

  27. Sanai N, Berger MS. Intraoperative stimulation techniques for functional pathway preservation and glioma resection. Neurosurg Focus. 2010; 28(2):E1.

  28. Salvati M, Pichierri A, Piccirilli M, et al. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. J Neurosurg. 2012; 117(2):204-11.

  29. Karnofsky DA Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. En: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. Columbia Univ Press. 1949. p. 196.

  30. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.

  31. Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAGlio. Neuro-Oncology. 2012;14(Suppl 6):vi101-5.

  32. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2013;31(Suppl) [abstract 1].

  33. NCCN Clinical Practice Guidelines in Oncology, Central Nervous System Cancers, Version I. 2014. NCCN.org.

  34. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-26.



>Revistas >Gaceta Médica de México >Año2015, No. 3
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019